Current Drug Regulatory Status of Advanced Drug Evaluation System in Korea

被引:0
|
作者
Pork I.-S. [1 ]
Kim D.S. [2 ]
机构
[1] Pharmaceutical Standardization and Cardiovascular Drug Division, Drug Evaluation Department, Korea Food and Drug Administration, Seoul
[2] Toxicological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, 122-70, 194 Tongiro, Eunpyeong-gu
关键词
CTD; Drug approval; GMP; GRP; IND; KFDA; Korea;
D O I
10.1177/009286150904300108
中图分类号
学科分类号
摘要
The pharmaceutical industry is a high-risk and high value-added industry, because the risk of failure in research and development is considerable. However, successful development will allow a company to get high returns. The market scale of the pharmaceutical industry has been increasing in the world and the Korean market is changing to focus on quality of life drugs owing to people's increased income levels and changing lifestyles. Drug products are important for the prevention, diagnosis, and treatment of diseases, and the development of drug products has resulted in improved quality of life, health maintenance, and considerable benefits to individuals as well as the national economy. However, since drug products carry the risks of adverse reactions, they have to satisfy the two important criteria of safety and efficacy. Therefore, the Korean government has implemented a drug safety management system, including one for authorization of drug products. Recently, one of the most important issues in the Korean pharmaceutical industry has been the signing of the Korea-US FTA (Free Trade Agreement), which will promote rapid and widespread competition. The pharmaceutical industry will also face the challenges of a more competitive environment. For sustainable growth and development of the Korean pharmaceutical industry in this rapidly changing environment, the balanced harmonization of the industry's strategic R&S efforts and the government's positive policies is essential. © 2009, Drug Information Association. All rights reserved.
引用
收藏
页码:41 / 46
页数:5
相关论文
共 50 条
  • [21] Current Regulatory System for Xenotransplantation Research in Korea
    Kwon, Ivo
    XENOTRANSPLANTATION, 2009, 16 (05) : 377 - 377
  • [22] Current Status of Alginate in Drug Delivery
    Hariyadi, Dewi Melani
    Islam, Nazrul
    ADVANCES IN PHARMACOLOGICAL AND PHARMACEUTICAL SCIENCES, 2020, 2020
  • [23] DRUG REGULATORY SYSTEM OF UNITED-STATES FOOD AND DRUG ADMINISTRATION - DEFENSE OF CURRENT REQUIREMENTS FOR SAFETY AND EFFICACY
    SIMMONS, HE
    INTERNATIONAL JOURNAL OF HEALTH SERVICES, 1974, 4 (01): : 95 - 107
  • [24] CURRENT STATUS OF DRUG THERAPY IN TUBERCULOSIS
    不详
    AMERICAN REVIEW OF TUBERCULOSIS, 1950, 61 (03): : 436 - 440
  • [25] Current Status of Drug Eluting Stents
    Kipshidze, Nicholas
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (36) : 3977 - 3977
  • [26] CURRENT STATUS OF HEMOPERFUSION FOR DRUG INTOXICATION
    ROSENBAUM, JL
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1978, 1 (06): : 252 - 253
  • [27] Transungual drug delivery: Current status
    Elkeeb, Rania
    AliKhan, Ali
    Elkeeb, Laila
    Hui, Xiaoying
    Maibach, Howard I.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 384 (1-2) : 1 - 8
  • [28] ANTIHYPERTENSIVE DRUG THERAPY - CURRENT STATUS
    BREST, AN
    MOYER, JH
    DISEASES OF THE CHEST, 1962, 41 (05): : 582 - 587
  • [29] Current status of drug repositioning in hematology
    Ohmoto, Akihiro
    Fuji, Shigeo
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (11) : 1005 - 1011
  • [30] Drug delivery system targeting advanced hepatocellular carcinoma: Current and future
    Zhang, Xue
    Ng, Huei Leng Helena
    Lu, Aiping
    Lin, Congcong
    Zhou, Limin
    Lin, Ge
    Zhang, Yanbo
    Yang, Zhijun
    Zhang, Hongqi
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2016, 12 (04) : 853 - 869